Lactiga™ is an award-winning, venture-backed biotherapeutics company developing novel biologics to treat and prevent infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. We are unlocking the full therapeutic value of human milk to create the next generation of anti-infectives that can battle even the world’s most dangerous pathogens.

Developing novel antibodies for mucosal infections in rare immunodeficiencies

Signup for updates below:


25-90% of individuals with primary immunodeficiencies will eventually develop complications.

Recurrent ear infections, sinusitis, pneumonia, and diarrhea are the most common symptoms in patients with Selective IgA Deficiency (SIgAD).

The prevalence of SIgAD is over 1 in 700, accounting for millions worldwide.

Common Variable Immune Deficiency (CVID)affects over
1 in 50,000 people and is classified as a rare disease.

What conditions are we focusing on?

Respiratory and gastrointestinal infections, which are common in patients with Primary Immunodeficiency Diseases (PIDD).

What are maternal antibodies?

They are large proteins, derived from a mother’s breastmilk, that bind and neutralize pathogens.

Has this been done?

The novelty of our work is reflected in our granted US, Canadian and Japanese patents.

With Support From

The search for better
treatment options is on

There are millions of immunodeficient patients of all ages worldwide, facing costly treatments and frequent hospitalizations.

If you’re a patient suffering from an antibody deficiency, we’d love to hear from you — your journey motivates our work. If you’re interested in investment or partnership opportunities, let’s have a discussion.